What is the dosage of Vebreltinib?

Vebreltinib is an oral small molecule MET inhibitor, used to treat patients with MET amplification or exon 14 skipping mutation-positive non-small cell lung cancer (NSCLC) and brain glioma. Recommended doses and administration methods vary depending on the tumor type. In patients with non-small cell lung cancer, it is recommended that the starting dose is 200 mg twice a day, once in the morning and once in the evening, to ensure the stability of the drug's blood concentration and maintain a sustained target inhibitory effect. For patients with glioma, due to the restriction of drug penetration by the blood-brain barrier, the recommended dose is increased to 300 mg orally twice a day, which helps ensure that the drug reaches an effective concentration in the brain tissue and thus exerts a therapeutic effect.

Bricitinib needs to be taken on an empty stomach, that is, no food for at least two hours before taking the medicine, and avoid eating within half an hour after taking the medicine, but drinking water is allowed. This medication requirement helps to fully absorb the drug, improve bioavailability, and reduce the impact of diet on the blood concentration of the drug. During the treatment process, patients should strictly follow the doctor's instructions and are not allowed to increase or decrease the dosage on their own to ensure efficacy and safety. As long as the patient tolerates the drug and achieves clinical benefit, treatment should be continued until disease progression or until the patient develops intolerable side effects.

During treatment, patients need to undergo regular imaging review and laboratory monitoring, including blood routine, liver and kidney function, and electrolyte levels, to evaluate efficacy and early detection of potential adverse reactions. If mild to moderate adverse reactions occur, such as nausea, mild fatigue, decreased appetite or fluctuations in blood indicators, the dosage can be appropriately adjusted or the dosing interval extended under the guidance of a doctor. For serious or persistent adverse reactions, seek medical treatment promptly and suspend medication or carry out symptomatic treatment if necessary.

Reference materials:https://www.asymbio.com.cn/